Tag: guifang dong

Protein palmitoylation helps to model the evolution of some forms of type 2 diabetes   

On February 7, Guifang Dong, PhD; Sangeeta Adak, PhD; Qiang Zhang, PhD; Chu Feng, MS; Li Yin, MD; Sarah Speck; Shuntaro Morikawa; Rie Asada, PhD; Fumihiko Urano, MD, PhD; Maria Remedi, PhD; Xiaochao Wei, PhD; Clay Semenkovich, MD; and collaborators had their work published in “Cell Metabolism.”  “Hyperinsulinemia often precedes type 2 diabetes,” and palmitoylation, […]

Semenkovich Lab and collaborators show the evolution of type 2 diabetes through APT1 deficiency 

On January 11, Semenkovich Lab and collaborators, had their research titled “Palmitoylation couples insulin hypersecretion with β cell failure in diabetes,” published in “Cell Metabolism.”  Hyperinsulinemia is known to often come before type 2 diabetes. In the study, they explain how acyl-protein thioesterase 1 (APT1) knockdown in nondiabetic islets causes insulin hypersecretion.  By using palmitoylation proteomics, their […]